Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Synta Pharamaceuticals (Nasdaq: SNTA ) has received a distressing two-star ranking.
With that in mind, let's take a closer look at Synta and see what CAPS investors are saying about the stock right now.
||Lexington, Mass. (2000)
||Co-Founder/CEO Dr. Safi Bahcall
CFO Keith Ehrlich
|Trailing-12-Month Return on Capital
||$44.7 million / $16.3 million
Kyowa Hakko Kirin
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 16% of the 168 members who have rated Synta believe the stock will underperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star zzlangerhans, touched on Synta's seemingly unsustainable valuation:
Hsp90 inhibitor Ganetespib is certainly in a lot of mid-stage trials but thus far in 2012 we haven't seen the kind of exciting interim data that management led us to expect. There's certainly a lot more info to come, but with Synta's poor developmental track record so far I see a market cap of [$450M] as excessively optimistic.
If you want market-thumping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit From the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.